By how much sitagliptin 100 and dapaglipflozin 10 can reduce hbA1c if given BD
sitagliptin dapagliflozin HbA1c reduction combination
sitagliptin 100mg once daily HbA1c reduction clinical trials efficacy
dapagliflozin 10mg HbA1c reduction clinical trial efficacy percentage
Important Clarification: Neither Drug is Dosed BD
HbA1c Reduction with Standard OD Dosing
Sitagliptin 100 mg OD (DPP-4 inhibitor)
| Context | Placebo-subtracted HbA1c reduction |
|---|---|
| Monotherapy (Phase III, 18-week) | -0.6% |
| Monotherapy in Japanese patients | -1.05% |
| Add-on to metformin | -0.65 to -0.75% |
| Real-world clinical practice (6 months) | ~-0.8% |
- Typical expected reduction: 0.5% to 0.9% (placebo-corrected)
- Greater reductions seen when baseline HbA1c is higher (>9%)
- No significant hypoglycemia as monotherapy
Dapagliflozin 10 mg OD (SGLT2 inhibitor)
| Context | HbA1c reduction |
|---|---|
| Monotherapy (24-week, vs placebo) | -0.89% (absolute); placebo-corrected -0.66% |
| Add-on to metformin (24-week) | Placebo-corrected -0.54% |
| Add-on to metformin + sitagliptin | Placebo-corrected -0.5% |
| Add-on to metformin + sulfonylurea | -0.86% absolute |
| Indian real-world data (6 months) | ~-1.0 to -1.5% |
- Typical expected reduction: 0.5% to 0.9% (similar to DPP-4 inhibitors)
- Greater reductions in patients with higher baseline HbA1c
- Additionally reduces weight (~2-3 kg) and systolic blood pressure (~3-4 mmHg)
Combined Use (Sitagliptin + Dapagliflozin)
- Sitagliptin: increases GLP-1/GIP, stimulates insulin secretion, suppresses glucagon
- Dapagliflozin: promotes urinary glucose excretion (~70-80g/day), insulin-independent
Summary Table
| Drug | Approved Dose | HbA1c Reduction (typical) |
|---|---|---|
| Sitagliptin | 100 mg OD | ~0.5 - 0.9% |
| Dapagliflozin | 10 mg OD | ~0.5 - 0.9% |
| Combination (both OD) | - | ~1.0 - 1.5% additive |
Create a clinical dosing reference card for DPP-4 and SGLT2 inhibitor combinations
fixed dose combination DPP4 SGLT2 inhibitor pills approved dosing brand names 2024
Qtern saxagliptin dapagliflozin Glyxambi empagliflozin linagliptin Steglujan ertugliflozin sitagliptin dosing renal impairment contraindications
Steglujan ertugliflozin sitagliptin dosing renal impairment eGFR contraindications 2024
A clean, professional clinical dosing reference card for fixed-dose combination (FDC) pills of DPP-4 inhibitors + SGLT2 inhibitors, designed for healthcare professionals. White background with a navy blue header bar at the top. Title in the header: "DPP-4 + SGLT2 Inhibitor Fixed-Dose Combination Reference Card" in bold white text. Subtitle: "Type 2 Diabetes Mellitus | For Clinical Use Only" in lighter white text. Below header, three drug card sections arranged side by side, each with a colored top strip and rounded corners: CARD 1 (blue strip): Brand: QTERN (AstraZeneca) Components: Dapagliflozin + Saxagliptin Available Strengths: 5mg/5mg | 10mg/5mg Dosing: One tablet OD, morning, with or without food Do NOT crush/cut/chew Renal Threshold: Do NOT initiate if eGFR <45 | Contraindicated eGFR <45, ESRD, Dialysis Drug Interaction: Avoid strong CYP3A4/5 inhibitors HbA1c Reduction: ~0.5–0.9% CARD 2 (teal/green strip): Brand: GLYXAMBI (Boehringer Ingelheim/Lilly) Components: Empagliflozin + Linagliptin Available Strengths: 10mg/5mg | 25mg/5mg Dosing: Start 10mg/5mg OD morning; may increase to 25mg/5mg With or without food Renal Threshold: Assess before initiating. Not recommended eGFR <30 | Contraindicated: Dialysis Note: Linagliptin requires NO renal dose adjustment HbA1c Reduction: ~0.5–1.0% CARD 3 (purple strip): Brand: STEGLUJAN (MSD/Merck) Components: Ertugliflozin + Sitagliptin Available Strengths: 5mg/100mg | 15mg/100mg Dosing: One tablet OD; may uptitrate to 15mg/100mg With or without food Renal Threshold: Not recommended eGFR <45 | Contraindicated eGFR <30, ESRD, Dialysis Withhold 4 days before major surgery HbA1c Reduction: ~0.5–1.0% Below the three cards, a shared warnings section in a light yellow box with a warning icon: Title: "Common Precautions for ALL FDC Combinations" Bullet points: - Not for Type 1 DM or Diabetic Ketoacidosis - Monitor for genital mycotic infections and UTI (SGLT2 effect) - Risk of Fournier's Gangrene (necrotizing fasciitis) - rare - Watch for volume depletion/hypotension in elderly/diuretics - Monitor for pancreatitis (DPP-4 effect) - Reduce insulin/sulfonylurea dose to avoid hypoglycemia - Hold before contrast procedures and major surgery At the bottom, a dark footer bar: "All doses once daily (OD) | Check current prescribing information | Not a substitute for clinical judgment" Clean, medical, professional design with good spacing and legible fonts. Color coded sections. No clipart. Clinical card layout.